| Literature DB >> 27936054 |
Marit G Tellevik1, Bjørn Blomberg1,2, Øyvind Kommedal3, Samuel Y Maselle4, Nina Langeland1,2, Sabrina J Moyo2,4.
Abstract
BACKGROUND: Faecal carriage of ESBL-producing bacteria is a potential risk for transmission and infection. Little is known about faecal carriage of antibiotic resistance in Tanzania. This study aimed to investigate the prevalence of faecal carriage of ESBL-producing Enterobacteriaceae and to identify risk factors for carriage among young children in Tanzania. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2016 PMID: 27936054 PMCID: PMC5148075 DOI: 10.1371/journal.pone.0168024
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Prevalence of ESBL screening positive children in the different study groups.
| Study group | ESBL screening positive (%) | P; OR (95% CI) |
|---|---|---|
| Community children | 29 (11.6) | 1 |
| Children hospitalized due to diarrhoea | 118 (47.2) | < 0.001; 6.81 (4.30–10.79) |
| Children hospitalized due to other diseases | 60 (58.3) | < 0.001; 10.63 (6.13–18.44) |
Susceptibility to antimicrobial agents for the ESBL screening positive bacteria.
| Prevalence of resistant isolates (%) | ||||||
|---|---|---|---|---|---|---|
| Antimicrobial agent | (N = 129) | (N = 139) | (N = 2) | (N = 11) | (N = 1) | (N = 2) |
| Aztreonam | 97.7 | 99.3 | 100 | 100 | 0 | 50 |
| Cefepime | 97.7 | 98.6 | 100 | 90.9 | 0 | 50 |
| Cefotaxime | 99.2 | 100 | 100 | 100 | 0 | 50 |
| Cefoxitin | 15.5 | 1.4 | 0 | 100 | 0 | 0 |
| Ceftazidime | 96.9 | 97.8 | 100 | 100 | 0 | 50 |
| Chloramphenicol | 41.9 | 71.2 | 100 | 81.8 | 100 | 0 |
| Ciprofloxacin | 62.8 | 17.3 | 100 | 63.6 | 100 | 0 |
| Doxycycline | 80.6 | 25.2 | 0 | 54.5 | 100 | 0 |
| Fosfomycin | 0 | 1.4 | 0 | 0 | 0 | 0 |
| Gentamicin | 77.5 | 92.8 | 100 | 90.9 | 0 | 50 |
| Meropenem | 0 | 0 | 0 | 0 | 0 | 0 |
| Piperacillin-Tazobactam | 45.7 | 84.2 | 100 | 36.4 | 0 | 50 |
| Tigecycline | 0 | 7.2 | 0 | 0 | 0 | 0 |
| Trimethoprim-Sulfamethoxazole | 98.4 | 99.3 | 100 | 81.8 | 100 | 0 |
| Multidrug-resistance I | 93.8 | 94.2 | 100 | 81.8 | 100 | 0 |
| Multidrug-resistance II | 50.4 | 14.4 | 100 | 63.6 | 0 | 0 |
1EUCAST guidelines applied.
2CLSI guidelines applied.
3Zone diameter breakpoints validated for E. coli only.
4Multidrug-resistance I defined as resistance to three or more of the antibacterial agents in the table.
5Multidrug-resistance II defined as resistance to ciprofloxacin, gentamicin and trimethoprim-sulfamethoxazole.
Characteristics of faecal carriage of ESBL screening positive bacteria among children in Dar es Salaam, Tanzania.
| Characteristics | ESBL screening positive children | ||||
|---|---|---|---|---|---|
| NChildren | n (%) | Univariate | Multivariate | Multivariate | |
| P; OR (95% CI) | P; OR (95% CI) | P; OR (95% CI) | |||
| Male | 361 | 134 (37.1) | 0.078;1.37 (0.97–1.94) | 0.24; 1.27 (0.85–1.91) | 0.58; 1.20 (0.63–2.31) |
| Female | 242 | 73 (30.2) | 1 | 1 | 1 |
| ≤ 12 months | 372 | 161 (43.3) | <0.001; 3.07 (2.09–4.50) | 0.012; 1.82 (1.14–2.91) | 0.55; 1.25 (0.61–2.54) |
| 231 | 46 (19.9) | 1 | 1 | 1 | |
| Ilala | 289 | 89 (30.8) | 1 | 1 | 1 |
| Temeke | 135 | 44 (32.6) | 0.710; 1.09 (0.70–1.68) | 0.91; 1.03 (0.62–1.70) | 0.40; 1.55 (0.56–4.29) |
| Kinondoni | 179 | 74 (41.3) | 0.020; 1.58 (1.07–2.34) | 0.001; 2.62 (1.49–4.60) | 0.014; 3.34 (1.28–8.72) |
| Higher level | 9 | 7 (77.8) | 0.017; 6.90 (1.42–33.50) | 0.34; 2.19 (0.43–11.16) | P = 1.0 |
| Secondary, Primary and below | 594 | 200 (33.7) | 1 | 1 | 1 |
| Community | 250 | 29 (11.6) | 1 | 1 | 1 |
| Diarrhoea | 250 | 118 (47.2) | <0.001; 6.81 (4.30–10.79) | <0.001; 5.32 (3.13–9.04) | <0.001; 5.98 (2.28–17.72) |
| Other diseases | 103 | 60 (58.3) | <0.001; 10.63 (6.13–18.44) | <0.001; 10.08 (5.39–18.83) | <0.001; 34.32 (2.78–424.14) |
| Normal weight | 329 | 104 (31.6) | 1 | 1 | 1 |
| Underweight | 274 | 103 (37.6) | 0.12; 1.30 (0.93–1.83) | 0.15; 1.42 (0.89–2.29) | 0.99; 1.00 (0.48–2.09) |
| Normal | 257 | 68 (26.5) | 1 | 1 | 1 |
| Stunted | 346 | 139 (40.2) | <0.001; 1.87 (1.31–2.65) | 0.12; 1.45 (0.91–2.31) | 0.20; 1.65 (0.76–3.56) |
| Normal | 454 | 163 (35.9) | 1 | 1 | 1 |
| Wasting | 149 | 44 (29.5) | 0.16; 0.75 (0.50–1.12) | 0.48; 0.83 (0.48–1.41) | 0.15; 0.50 (0.20–1.29) |
| Positive | 29 | 26 (89.7) | <0.001; 42.53 (12.43–145.57) | Not applicable | 0.001; 9.99 (2.52–39.57) |
| Negative | 319 | 55 (16.9) | 1 | 1 | |
| No use | 378 | 100 (26.5) | 1 | 1 | 1 |
| Used | 225 | 107 (47.6) | <0.001; 2.52 (1.78–3.57) | 0.022; 1.61 (1.07–2.41) | 0.37; 1.38 (0.68–2.80) |
N: Total number of samples tested; n: number of positive samples; WAZ: Weight-for-age-Z-score; LAZ: Length-for-age-Z-score; WLZ: Weight-for-length-Z-score
1Use of antibiotics during the last 14 days prior to inclusion, or on inclusion.
2 and 3 Multivariate analysis for all children (n = 603) and only children with known HIV status (n = 348), respectively.
Fig 1Prevalence of ESBL carriage in different age groups.
The graph shows the prevalence (%) of ESBL carriage among the study participants when categorized into five different age groups.
Prevalence of ESBL carriage among children admitted at each of the study hospitals.
| Hospital | ESBL screening positive (%) | P; OR (95% CI) |
|---|---|---|
| Muhimbili National Hospital | 98/129 (76) | < 0.001; 9.06 (4.44–18.59) |
| Amana District Hospital | 65/166 (39.2) | 0.07; 1.85 (0.95–3.59) |
| Temeke District Hospital | 15/58 (25.9) | 1 |